147 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
52
Discovery of 4-((3'R,4'S,5'R)-6¿-Chloro-4'-(3-chloro-2-fluorophenyl)-1'-ethyl-2¿-oxodispiro[cyclohexane-1,2'-pyrrolidine-3',3¿-indoline]-5'-carboxamido)bicyclo[2.2.2]octane-1-carboxylic Acid (AA-115/APG-115): A Potent and Orally Active Murine Double Minute 2 (MDM2) Inhibitor in Clinical Deve
University of Michigan Comprehensive Cancer Center
40
Rational design and synthesis of 1,5-disubstituted tetrazoles as potent inhibitors of the MDM2-p53 interaction.
Jagiellonian University
1
Discovery of novel polycyclic spiro-fused carbocyclicoxindole-based anticancer agents.
Sichuan University and Collaborative Innovation Center For Biotherapy
10
Lead Optimization of 2-Phenylindolylglyoxylyldipeptide Murine Double Minute (MDM)2/Translocator Protein (TSPO) Dual Inhibitors for the Treatment of Gliomas.
University of Pisa
42
Structure-activity relationship study of 4-substituted piperidines at Leu26 moiety of novel p53-hDM2 inhibitors.
Merck Research Laboratories
4
Peptide-based inhibitors of protein-protein interactions.
Wroclaw University of Technology
8
Identification of a new p53/MDM2 inhibitor motif inspired by studies of chlorofusin.
University of East Anglia
11
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
Novartis Institutes For Biomedical Research
8
Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 Inhibitors) in clinical trials for cancer treatment.
University of Michigan Comprehensive Cancer Center and Departments of Internal Medicine
26
Discovery of AM-7209, a potent and selective 4-amidobenzoic acid inhibitor of the MDM2-p53 interaction.
Amgen
8
Discovery of DS-5272 as a promising candidate: A potent and orally active p53-MDM2 interaction inhibitor.
Daiichi Sankyo
33
Optimization beyond AMG 232: discovery and SAR of sulfonamides on a piperidinone scaffold as potent inhibitors of the MDM2-p53 protein-protein interaction.
Amgen
22
Design of chemically stable, potent, and efficacious MDM2 inhibitors that exploit the retro-mannich ring-opening-cyclization reaction mechanism in spiro-oxindoles.
University of Michigan Comprehensive Cancer Center and Departments of Internal Medicine
5
Pivotal Role of an Aliphatic Side Chain in the Development of an HDM2 Inhibitor.
Merck Research Laboratories
17
Discovery of 1-arylpyrrolidone derivatives as potent p53-MDM2 inhibitors based on molecule fusing strategy.
Second Military Medical University
14
Design, synthesis and in vitro and in vivo antitumour activity of 3-benzylideneindolin-2-one derivatives, a novel class of small-molecule inhibitors of the MDM2-p53 interaction.
Peking Union Medical College
15
Hot spot-based design of small-molecule inhibitors for protein-protein interactions.
University of Utah
14
Tetra-substituted imidazoles as a new class of inhibitors of the p53-MDM2 interaction.
Novartis Institutes For Biomedical Research
47
Novel inhibitors of the MDM2-p53 interaction featuring hydrogen bond acceptors as carboxylic acid isosteres.
Amgen
23
Selective and potent morpholinone inhibitors of the MDM2-p53 protein-protein interaction.
Amgen
11
Core modification of substituted piperidines as novel inhibitors of HDM2-p53 protein-protein interaction.
Merck Research Laboratories
46
Discovery of AMG 232, a potent, selective, and orally bioavailable MDM2-p53 inhibitor in clinical development.
Amgen
20
Discovery of Potent and Orally Active p53-MDM2 Inhibitors RO5353 and RO2468 for Potential Clinical Development.
Roche Pharma Research
26
5-Deazaflavin derivatives as inhibitors of p53 ubiquitination by HDM2.
University of Nottingham
12
Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development.
Roche Research Center
10
A potent small-molecule inhibitor of the MDM2-p53 interaction (MI-888) achieved complete and durable tumor regression in mice.
University of Michigan
3
Affinity-based screening of MDM2/MDMX-p53 interaction inhibitors by chemical array: identification of novel peptidic inhibitors.
Kyoto University
3
Functional consequences of retro-inverso isomerization of a miniature protein inhibitor of the p53-MDM2 interaction.
Southwest University
12
Benzimidazole-2-one: a novel anchoring principle for antagonizing p53-Mdm2.
University of Pittsburgh
14
Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical Development.
Roche Research Center
1
Synthesis and evaluation of an imidazole derivative-fluorescein conjugate.
University of Texas At Houston
23
Structure-activity relationship and antitumor activity of thio-benzodiazepines as p53-MDM2 protein-protein interaction inhibitors.
TBA
2
Chemical modulators working at pharmacological interface of target proteins.
Korea University College of Pharmacy Sejong-Ro
18
Discovery of novel dihydroimidazothiazole derivatives as p53-MDM2 protein-protein interaction inhibitors: synthesis, biological evaluation and structure-activity relationships.
Daiichi Sankyo
1
AM-8553: a novel MDM2 inhibitor with a promising outlook for potential clinical development.
University of Michigan Comprehensive Cancer Center
10
Unbiased binding assays for discovering small-molecule probes and drugs.
Broad Institute of Harvard and Mit
2
Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomics.
Yale University
4
NMR screening for lead compounds using tryptophan-mutated proteins.
Institute For Biochemistry
8
Reaching for high-hanging fruit in drug discovery at protein-protein interfaces.
University of California San Francisco
91
Isoindolinone inhibitors of the murine double minute 2 (MDM2)-p53 protein-protein interaction: structure-activity studies leading to improved potency.
Newcastle University
20
Synthesis of cell-permeable stapled peptide dual inhibitors of the p53-Mdm2/Mdmx interactions via photoinduced cycloaddition.
State University of New York
8
Functional profiling of p53-binding sites in Hdm2 and Hdmx using a genetic selection system.
Purdue University
10
Potent and orally active small-molecule inhibitors of the MDM2-p53 interaction.
University of Michigan
8
Discovery and optimization of chromenotriazolopyrimidines as potent inhibitors of the mouse double minute 2-tumor protein 53 protein-protein interaction.
Amgen
5
Discovery of new pyridoacridine alkaloids from Lissoclinum cf. badium that inhibit the ubiquitin ligase activity of Hdm2 and stabilize p53.
National Cancer Institute-Frederick
2
Design, Synthesis, and Biological Evaluation of Lysine-Stapled Peptide Inhibitors of p53-MDM2/MDMX Interactions with Potent Antitumor Activity In Vivo.
Chongqing University
2
Rational design, synthesis, and biophysical characterization of a peptidic MDM2-MDM4 interaction inhibitor.
Universite degli Studi di Perugia
1
An overview of PROTACs targeting MDM2 as a novel approach for cancer therapy.
University of Chinese Academy of Sciences
39
Cellular, Structural Basis, and Recent Progress for Targeting Murine Double Minute X (MDMX) in Tumors.
Yantai University
7
Synthesis and biological evaluation of 4-imidazolidinone-containing compounds as potent inhibitors of the MDM2/p53 interaction.
Nanjing University of Chinese Medicine
1
An overview of the functions of p53 and drugs acting either on wild- or mutant-type p53.
Shandong University
3
Discovery of ganoderic acid A (GAA) PROTACs as MDM2 protein degraders for the treatment of breast cancer.
Chinese Academy of Medical Sciences and Peking Union Medical College
57
Discovery of JN122, a Spiroindoline-Containing Molecule that Inhibits MDM2/p53 Protein-Protein Interaction and Exerts Robust In Vivo Antitumor Efficacy.
Shanghai Institute of Materia Medica
53
Structure-based discovery of novel α-aminoketone derivatives as dual p53-MDM2/MDMX inhibitors for the treatment of cancer.
Nanjing University of Chinese Medicine
5
Discovery of Sulanemadlin (ALRN-6924), the First Cell-Permeating, Stabilized α-Helical Peptide in Clinical Development.
Aileron Therapeutics
4
DNA-Encoded Macrocyclic Peptide Libraries Enable the Discovery of a Neutral MDM2-p53 Inhibitor.
Unnatural Products
1
Discovery of MD-224 as a First-in-Class, Highly Potent, and Efficacious Proteolysis Targeting Chimera Murine Double Minute 2 Degrader Capable of Achieving Complete and Durable Tumor Regression.
TBA
2
2-Aminothiophene scaffolds: Diverse biological and pharmacological attributes in medicinal chemistry.
Xinjiang Technical Institute of Physics and Chemistry
8
Natural spirocyclic alkaloids and polyphenols as multi target dementia leads.
Rmit University
11
Recent applications of covalent chemistries in protein-protein interaction inhibitors.
University of Maryland
12
Homobivalent, Trivalent, and Covalent PROTACs: Emerging Strategies for Protein Degradation.
Second Military Medical University
23
Recent Progress and Clinical Development of Inhibitors that Block MDM4/p53 Protein-Protein Interactions.
University of Chinese Academy of Sciences
4
Diversity-oriented synthesis as a tool to expand the chemical space of DNA-encoded libraries.
University of Florence
55
Structure-Based Discovery of MDM2/4 Dual Inhibitors that Exert Antitumor Activities against MDM4-Overexpressing Cancer Cells.
Shanghai Institute of Materia Medica
23
Discovery of a selective and covalent small-molecule inhibitor of BFL-1 protein that induces robust apoptosis in cancer cells.
Yancheng Teachers University
28
The Alpha Keto Amide Moiety as a Privileged Motif in Medicinal Chemistry: Current Insights and Emerging Opportunities.
Niddk
2
Stapled peptides as scaffolds for developing radiotracers for intracellular targets: Preliminary evaluation of a radioiodinated MDM2-binding stapled peptide in the SJSA-1 osteosarcoma model.
Duke University Medical Center
1
Emerging targeted protein degradation tools for innovative drug discovery: From classical PROTACs to the novel and beyond.
China Pharmaceutical University
6
Structure-based design, synthesis, and biological evaluation of novel 1,4-diazepines as HDM2 antagonists.
Johnson & Johnson Pharmaceutical Research and Development
8
Cyclic Peptide Screening Methods for Preclinical Drug Discovery.
University of Washington
3
Discovery of MDM2-p53 and MDM4-p53 protein-protein interactions small molecule dual inhibitors.
Universidade De Lisboa
2
Development of MDM2 degraders based on ligands derived from Ugi reactions: Lessons and discoveries.
University of Wisconsin-Madison
31
Design, synthesis, and biological evaluation of nitroisoxazole-containing spiro[pyrrolidin-oxindole] derivatives as novel glutathione peroxidase 4/mouse double minute 2 dual inhibitors that inhibit breast adenocarcinoma cell proliferation.
Chengdu University of Traditional Chinese Medicine
16
Rational Design of Right-Handed Heterogeneous Peptidomimetics as Inhibitors of Protein-Protein Interactions.
University of South Florida
11
hDM2 protein-binding peptides screened from stapled α-helical peptide phage display libraries with different types of staple linkers.
Tokyo Institute of Technology
9
Opportunities for Tapping into Three-Dimensional Chemical Space through a Quaternary Carbon.
St. John'S University
11
HOPPI-NMR: Hot-Peptide-Based Screening Assay for Inhibitors of Protein-Protein Interactions by NMR.
University of Naples "Federico Ii
3
Design, synthesis and biological evaluation of novel antitumor spirodihydrothiopyran-oxindole derivatives.
Shaanxi University of Science & Technology
9
Enhancing the Cell Permeability of Stapled Peptides with a Cyclic Cell-Penetrating Peptide.
The Ohio State University
49
Hitting on the move: Targeting intrinsically disordered protein states of the MDM2-p53 interaction.
University of Groningen
3
Development of selective small molecule MDM2 degraders based on nutlin.
University of Wisconsin-Madison
27
The past, present and future of potential small-molecule drugs targeting p53-MDM2/MDMX for cancer therapy.
Sichuan University
14
α-Helix-Mimicking Sulfono-γ-AApeptide Inhibitors for p53-MDM2/MDMX Protein-Protein Interactions.
University of South Florida
7
Simple Structural Modifications Converting a Bona fide MDM2 PROTAC Degrader into a Molecular Glue Molecule: A Cautionary Tale in the Design of PROTAC Degraders.
TBA
22
Bcl-2/MDM2 Dual Inhibitors Based on Universal Pyramid-Like α-Helical Mimetics.
Dalian University of Technology
8
2,30-Bis(10H-indole) heterocycles: New p53/MDM2/MDMX antagonists.
University of Groningen
1
Lead optimization of novel p53-MDM2 interaction inhibitors possessing dihydroimidazothiazole scaffold.
Daiichi Sankyo
1
Hexylitaconic acid: a new inhibitor of p53-HDM2 interaction isolated from a marine-derived fungus, Arthrinium sp.
Kanazawa University
6
The development of piperidinones as potent MDM2-P53 protein-protein interaction inhibitors for cancer therapy.
International Institute For Translational Chinese Medicine
11
In vitro and in vivo characterization of a novel, highly potent p53-MDM2 inhibitor.
Novartis Institutes For Biomedical Research
7
Role of p53 circuitry in tumorigenesis: A brief review.
Jss Academy of Higher Education and Research
1
Unique arginine array improves cytosolic localization of hydrocarbon-stapled peptides.
Yale University
24
Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents.
East China University of Science and Technology
16
Simultaneous Targeting of RGD-Integrins and Dual Murine Double Minute Proteins in Glioblastoma Multiforme.
University of Naples Federico II
22
1,4,5-Trisubstituted Imidazole-Based p53-MDM2/MDMX Antagonists with Aliphatic Linkers for Conjugation with Biological Carriers.
Jagiellonian University
6
d-Amino acid mutation of PMI as potent dual peptide inhibitors of p53-MDM2/MDMX interactions.
University of Maryland
19
Design, synthesis and biological evaluation of novel antitumor spirotetrahydrothiopyran-oxindole derivatives as potent p53-MDM2 inhibitors.
East China University of Science & Technology
15
Computer-Aided Identification and Lead Optimization of Dual Murine Double Minute 2 and 4 Binders: Structure-Activity Relationship Studies and Pharmacological Activity.
University of Naples Federico II
6
Investigation of the inhibitory mechanism of apomorphine against MDM2-p53 interaction.
Kyoto University
1
Amorphous Form of (S)-2-(5-((3-Ethoxypyridin-2-YL)Oxy)Pyridin-3-YL)-N-(Tetrahydrofuran-3-YL)Pyrimidine-5-Carboxamide
Pfizer
18
5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2 Pyridyl]Amino]Pyrazine-2-carbonitrile and therapeutic uses thereof
Cancer Research Technology
9
Method for controlling hematophagous or sap-feeding arthropods
Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
219
Thienopyridine carboxamides as ubiquitin-specific protease inhibitors
Valo Early Discovery
174
Compounds antagonizing A3 adenosine receptor, method for preparing them, and medical-use thereof
Handok
18
5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2-pyridyl]amino]pyrazine-2-carbonitrile and therapeutic uses thereof
Cancer Research Technology
573
2-Acylamidomethyl and sulfonylamidomethyl benzoxazine carbamates for inhibition of RORgamma activity and the treatment of disease
Lycera
53
Aromatic heterocyclic compounds and their application in pharmaceuticals
Sunshine Lake Pharma
492
AMPK-activating heterocyclic compounds and methods for using the same
Rigel Pharmaceuticals
6
γ-aminobutyric acid (GABA) analogues for the treatment of pain and other disorders
Novassay
4
Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor.
Wyeth Research
3
Comparison of CGS 15943, ZM 241385 and SCH 58261 as antagonists at human adenosine receptors.
Schering-Plough Research Institute
6
Identification and characterization of new inhibitors of fungal homoserine kinase.
Mcmaster University
6
Cloning and functional expression of cDNAs encoding human and rat pancreatic polypeptide receptors.
Amgen
16
Synthesis and structure-activity relationship of the isoindolinyl benzisoxazolpiperidines as potent, selective, and orally active human dopamine D4 receptor antagonists.
Aventis Pharmaceuticals
4
Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity.
Janssen Research Foundation
6
Novel protein kinase D inhibitors cause potent arrest in prostate cancer cell growth and motility.
University of Pittsburgh
2
Sequential mechanism of assembly of multidrug efflux pump AcrAB-TolC.
University of Oklahoma
887
Heterocycle derivatives for treating TRPM3 mediated disorders
Katholieke Universiteit Leuven
3
Insights into antifolate resistance from malarial DHFR-TS structures.
Mahidol University
7
Structural insight into the pharmacophore pocket of human glutamate carboxypeptidase II.
Nci-Fcrdc
31
Design, synthesis, and biological evaluation of peptidomimetic inhibitors of factor XIa as novel anticoagulants.
Daiichi Asubio Medical Research Laboratories
27
Protease inhibitors: synthesis of matrix metalloproteinase and bacterial collagenase inhibitors incorporating 5-amino-2-mercapto-1,3,4-thiadiazole zinc binding functions.
Universita Degli Studi Di Firenze
6
Structure-based optimization of novel azepane derivatives as PKB inhibitors.
Roche Diagnostics